阿哌沙班
医学
华法林
心房颤动
内科学
冲程(发动机)
腹膜透析
倾向得分匹配
危险系数
心脏病学
透析
肾功能
比例危险模型
心力衰竭
心房颤动的处理
回顾性队列研究
肾脏疾病
达比加群
抗凝剂
重症监护医学
大出血
急性肾损伤
外科
作者
Mingyue He,Kevin F. Erickson,Hania S. Kassem,Maria E. Montez‐Rath,Tara I. Chang,Wolfgang C. Winkelmayer,Jingbo Niu
摘要
INTRODUCTION: Apixaban reduces thromboembolic events, bleeding, and mortality compared with warfarin in patients with nonvalvular atrial fibrillation (NVAF). However, evidence in patients with kidney failure (KF) receiving peritoneal dialysis (PD) is limited. We evaluated the safety and effectiveness of apixaban versus warfarin in this population. METHODS: Using the US Renal Data System, we identified Medicare beneficiaries on PD with newly diagnosed NVAF (2014-2019) who had no prior oral anticoagulation (OAC) use. We included patients initiating apixaban or warfarin within 30 days after NVAF diagnosis. After propensity matching, we estimated the hazard ratios for thromboembolic events, bleeding events, and mortality using Cox models accounting for competing risks, where applicable, and using both intent-to-treat and as-treated (AT) approaches. RESULTS: -VASc score was 4 (IQR 3-5). In intent-to-treat analyses, hazards of ischemic stroke (hazard ratio [HR] = 0.92; 95% CI: 0.42-2.01) and the composite of other thromboembolic outcomes with cardiovascular death (HR = 0.90; 95% CI: 0.66-1.22) did not differ between groups. The hazards of clinically important bleeding (HR = 0.81; 95% CI: 0.62-1.07), major bleeding, intracranial hemorrhage, and all-cause mortality also did not differ between groups. Findings were consistent in AT analyses. CONCLUSION: Among PD patients with newly diagnosed NVAF, we observed no statistically significant differences between apixaban and warfarin for effectiveness or bleeding outcomes. Given the challenges of warfarin management in KF, apixaban may represent a more practical option when anticoagulation is pursued.
科研通智能强力驱动
Strongly Powered by AbleSci AI